Transcainide

Modify Date: 2024-06-10 18:36:37

Transcainide Structure
Transcainide structure
Common Name Transcainide
CAS Number 88296-62-2 Molecular Weight 373.53200
Density 1.13g/cm3 Boiling Point 529.4ºC at 760 mmHg
Molecular Formula C22H35N3O2 Melting Point N/A
MSDS N/A Flash Point 274ºC

 Use of Transcainide


Transcainide (R 54718) is an orally active antiarrhythmic agent[1].

 Names

Name Transcainide

 Transcainide Biological Activity

Description Transcainide (R 54718) is an orally active antiarrhythmic agent[1].
Related Catalog
References

[1]. R Stroobandt, Evaluation of the efficacy and tolerance of the antiarrhythmic agent transcainide (R 54718). Eur J Clin Pharmacol. 1987;32(5):449-56.  

 Chemical & Physical Properties

Density 1.13g/cm3
Boiling Point 529.4ºC at 760 mmHg
Molecular Formula C22H35N3O2
Molecular Weight 373.53200
Flash Point 274ºC
Exact Mass 373.27300
PSA 55.81000
LogP 2.95250
Index of Refraction 1.58

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TM6060000
CHEMICAL NAME :
4-Piperidinecarboxamide, 4-(dimethylamino)-N-(2,6-dimethylphenyl)-1-(2-hydroxy cyclohexyl)-, trans-(+-)-
CAS REGISTRY NUMBER :
88296-62-2
LAST UPDATED :
198910
DATA ITEMS CITED :
4
MOLECULAR FORMULA :
C22-H35-N3-O2
MOLECULAR WEIGHT :
373.60

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
4830 ug/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 287,272,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
440 ug/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - effect, not otherwise specified Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 287,272,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
1500 ug/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold Gastrointestinal - hypermotility, diarrhea
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 287,272,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
440 ug/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Gastrointestinal - hypermotility, diarrhea Gastrointestinal - nausea or vomiting
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 287,272,1987